Ionis Pharmaceuticals Inc at BMO Capital Markets Growth & ESG Conference (Virtual) Transcript
Good afternoon, everyone. My name is Do Kim, one of the biotech analysts here at BMO. Our next presentation and fireside chat is with Ionis Pharmaceuticals. And with us today is CEO, Brett Monia. Ionis is clearly one of the leading biotech companies in the RNA targeting antisense therapeutic space. Brett, I want to thank you for joining us today. And perhaps a start is -- for the investors less familiar with therapeutics and biotech, provide us a brief background on the company and the platform of your antisense drug.
Sure. Happy to, Do. And thanks for the invitation. It's a pleasure to be here. So for those not familiar with Ionis, we are the pioneer of the field of antisense technology, technology that we set out to create years ago. And along the way, what we essentially did was create and validate not only the antisense field, but we actually created the sector you just referred to Do as -- referred to as RNA therapeutics with
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |